Published in Medical Letter on the CDC and FDA, October 23rd, 2005
The patent on the branded product by Galderma expires on June 6, 2006.
MetroGel generated approximately $75 million in sales in 2004. It is indicated for the treatment of rosacea.
MetroGel represents the eighth FDA approval and the third first-generic for Fougera thus far in 2005. "Our success in developing and marketing a consistent stream of topical products is gratifying. We continue...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA